Lirilumab

Lirilumab is a human IgG1 monoclonal antibody being investigated as an immunotherapeutic agent for the treatment of cancer. It targets the killer cell immunoglobulin-like receptor (KIR) 2DL1, 2DL2, and 2DL3 receptors, which are inhibitory receptors expressed on natural killer (NK) cells and some T cells.

Lirilumab's mechanism of action involves blocking these inhibitory KIR receptors. By preventing the KIR receptors from binding to their ligands (HLA-C molecules on tumor cells), lirilumab aims to enhance the activity of NK cells and T cells, allowing them to recognize and kill cancer cells more effectively. The blockade essentially releases the "brake" on these immune cells, enabling them to mount a stronger anti-tumor response.

Clinical trials have explored lirilumab as a monotherapy and in combination with other cancer treatments, including chemotherapy and other immunotherapies. Studies have focused on various cancer types, including hematological malignancies and solid tumors. Research is ongoing to determine the optimal use and efficacy of lirilumab in different cancer settings. The drug is still considered investigational and has not received regulatory approval for any specific indication as of my last knowledge update.